InventisBio Co. Ltd. A (688382) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of InventisBio Co. Ltd. A ¥2.56, price ¥19.07, upside -86.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch InventisBio Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
50‑month range ¥6.72 – ¥47.90 · fair‑value band ¥1.69 – ¥3.20 · the ¥19.07 price screens above the ¥2.56 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow InventisBio Co. Ltd. A in your weekly email
Every Wednesday you see whether InventisBio Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China.
Show more
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. The company also develops D"2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout. In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.
Stock analysis
InventisBio Co. Ltd. A (688382) currently trades at ¥19.07, while our model-based Fair Value estimate is ¥2.56, 86.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: ¥1.69 (bear) to ¥3.20 (bull), the price of ¥19.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
InventisBio Co. Ltd. A reported revenue of 37.3M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −317M CNY in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, 688382 screens richer than that median.
Fair Value models
Bear ¥1.69Fair Value ¥2.56Bull ¥3.20
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−86.6% · Bottom 25%
Profitability
Return on assets−12.1% · Below median
Operating margin (TTM)−117.0% · Bottom 25%
Growth and dividend
Revenue growth419.5% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.07× · Cheaper than median
P/S (TTM)22.98× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "InventisBio Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688382
Frequently asked questions
Is InventisBio Co. Ltd. A (688382) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥2.56 versus a price of ¥19.07, about −87% upside (overvalued).
What is the fair value of 688382?
Our model-based fair value for InventisBio Co. Ltd. A is ¥2.56 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥19.07.
What is the quality score of 688382?
InventisBio Co. Ltd. A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InventisBio Co. Ltd. A (688382)?
Our model-based price target is the fair value of ¥2.56 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario ¥1.69, optimistic scenario ¥3.20. It is a calculation from audited fundamentals, not an analyst target.
What is the InventisBio Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥2.56, about −87% upside versus a price of ¥19.07 (overvalued). Cautious scenario ¥1.69, optimistic scenario ¥3.20. The calculation is refreshed regularly with new filings.
What is the revenue of InventisBio Co. Ltd. A (688382)?
InventisBio Co. Ltd. A reported trailing-twelve-month revenue of about 71.6M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of InventisBio Co. Ltd. A (688382)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InventisBio Co. Ltd. A it is ¥2.56 per share (as of Sep 24, 2026), against a price of ¥19.07. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is InventisBio Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688382 trades above its calculated fair value: price ¥19.07, fair value ¥2.56, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688382?
No. The price is what the market pays today (¥19.07); the fair value is what the company's own numbers justify (¥2.56). For InventisBio Co. Ltd. A the two are ¥16.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is InventisBio Co. Ltd. A worth?
The market values InventisBio Co. Ltd. A at about 11.0B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥19.07; our models calculate a fair value of ¥2.56 per share.
What do the bullish and bearish scenarios say about 688382?
Our models span a range for InventisBio Co. Ltd. A: cautious scenario ¥1.69, base ¥2.56, optimistic ¥3.20 per share (as of Sep 24, 2026, price ¥19.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InventisBio Co. Ltd. A (688382)?
Balance-sheet figures for InventisBio Co. Ltd. A (as of Sep 24, 2026): return on equity −18.6%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 688382 from its 52-week high?
InventisBio Co. Ltd. A trades at ¥19.07, about 43% below its 52-week high of ¥33.40 and 19% above the low of ¥15.96 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.56 is for.
Which stocks are comparable to InventisBio Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InventisBio Co. Ltd. A stock attractive at the current price?
The data as of Sep 24, 2026: price ¥19.07, calculated fair value ¥2.56 (−87%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688382 calculated?
We run InventisBio Co. Ltd. A through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.56, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. InventisBio Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InventisBio Co. Ltd. A (688382)?
The closing price on Sep 30, 2026 was ¥19.07. Our model-based fair value is ¥2.56, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InventisBio Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥3.20). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥1.69 to ¥3.20) leaves room in how you read the outcome.
Key figures of InventisBio Co. Ltd. A
How large is the market capitalisation of InventisBio Co. Ltd. A (688382)?
The market capitalisation of InventisBio Co. Ltd. A is 11.0B CNY (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of InventisBio Co. Ltd. A (688382)?
Earnings per share at InventisBio Co. Ltd. A are ¥−0.5300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of InventisBio Co. Ltd. A (688382)?
The return on equity (ROE) of InventisBio Co. Ltd. A is −18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InventisBio Co. Ltd. A (688382)?
On an EBIT basis the return on assets of InventisBio Co. Ltd. A is −22.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InventisBio Co. Ltd. A (688382)?
The operating margin of InventisBio Co. Ltd. A is −117% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at InventisBio Co. Ltd. A (688382)?
Revenue at InventisBio Co. Ltd. A is growing +420% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does InventisBio Co. Ltd. A (688382) generate?
The free cash flow of InventisBio Co. Ltd. A is −162M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch InventisBio Co. Ltd. A in the live analysis
One click puts InventisBio Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
